NCT05905887 - Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Gastrointestinal Stromal Tumors

Interventions

DRUG

Rivoceranib Mesylate, Paclitaxel

"Paclitaxel will be administered at 80mg/m2/day every four weeks at Day 1, Day 8 and Day 15 per cycle. One cycle consists of 4 weeks (28 days).~Rivoceranib 400 mg orally once a day."

Trial Locations (1)

138-736

RECRUITING

Asan Medical Center, University of Ulsan College of Medicine, Seoul